Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients

NCT06796517 is registered in ClinicalTrials.gov with Sung-Soo Park as lead sponsor.

NCT NCT06796517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
Lead sponsor
Sung-Soo Park
Phase
Observational
Overall status
Recruiting
Start date
June 26, 2024
Completion date
December 31, 2025
Enrollment
72 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, diffuse large b cell lymphoma relapsed, high grade b-cell lymphoma, primary mediastinal large b-cell lymphoma, relapsed/refractory high grade b cell lymphoma